HLB Therapeutics (115450) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, HLB Therapeutics (115450) reported revenue of 69.6 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
202569.6 billion KRW-3.5 billion KRW-9.7 billion KRW[source]
202454.9 billion KRW-7.6 billion KRW-23.5 billion KRW[source]
202353.7 billion KRW-8.7 billion KRW-3.1 billion KRW[source]
202248.1 billion KRW-7.9 billion KRW-12.1 billion KRW[source]
202143.6 billion KRW-11.1 billion KRW-17.8 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025231.2 billion KRW52.6 billion KRW178.6 billion KRW[source]
2024231.1 billion KRW37.0 billion KRW194.1 billion KRW[source]
2023215.7 billion KRW28.2 billion KRW187.5 billion KRW[source]
2022196.5 billion KRW54.1 billion KRW142.4 billion KRW[source]
2021197.6 billion KRW58.4 billion KRW139.2 billion KRW[source]

Cash Flow

YearOperatingInvestingFinancingSource
2025-8.2 billion KRW-564 million KRW11.1 billion KRW[source]
20241.3 billion KRW-35.5 billion KRW28.4 billion KRW[source]
20233.3 billion KRW-20.2 billion KRW-5.3 billion KRW[source]
2022-8.8 billion KRW-41.9 billion KRW-3.3 billion KRW[source]
2021-11.3 billion KRW14.4 billion KRW82.9 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice